1+ week, 11+ hour ago   (243+ words) For the current analysis, the baseline time point before cycle 1 was emphasized, incorporating PET/CT imaging and baseline ctDNA. A total of 133 patients selected to receive 177Lu-PSMA‑617 were included. Treatment response was defined according to PSA50: Using baseline clinical data alone,…...

1+ day, 6+ hour ago   (1214+ words) Valerio Santarelli presents a multi-institutional study evaluating upper tract recurrence after radical cystectomy across 23 centers and roughly 1,800 patients. Of these, 85 patients underwent subsequent radical nephroureterectomy; 81 were propensity-matched 1:2 to 157 radical cystectomy-only controls. Dr. Santarelli reports positive ureteral margin carried the strongest…...

2+ day, 14+ hour ago   (822+ words) Adanma Ayanambakkam presents phase 1 data on darlifarnib, a farnesyltransferase inhibitor, combined with cabozantinib in renal cell carcinoma. The dose-escalation study enrolled 72 patients, escalating darlifarnib through 3, 5, and 8 mg alongside cabozantinib at 40 mg and then full dose at 60 mg. In cabozantinib-exposed patients,…...

2+ day, 16+ hour ago   (1083+ words) Thomas Seisen presents a systematic review and meta-analysis on pathologic complete response, or path-CR, as a surrogate for overall survival in neoadjuvant muscle-invasive bladder cancer trials. Dr. Seisen's team analyzed 12 studies, including eight randomized controlled trials, using an R-square threshold…...

2+ day, 23+ hour ago   (1015+ words) Todd Morgan discusses molecular testing and the PROTEUS trial in localized prostate cancer. On discordant Decipher® and Artera results, Dr. Morgan recommends ordering only one test per patient and notes that a high Decipher® score likely carries more weight than…...

3+ day, 49+ min ago   (793+ words) Avirup Guha presents a validated, machine learning-based cardiovascular risk score for prostate cancer patients starting androgen deprivation therapy or ARPIs. Dr. Guha built the tool using three cohorts, including the roughly 4,000-patient RADICAL PC1 cohort, and classifies patients as low, intermediate,…...

1+ week, 8+ hour ago   (218+ words) (UroToday.com) The 2026 ProsTIC annual meeting featured a PSMA imaging session and a presentation by Dr. Sidney Levy discussing the choice of the right PSMA radiotracer. Dr. Levy began by reviewing the current PSMA PET radiotracer landscape, including four tracers:…...

1+ week, 3+ hour ago   (384+ words) In PRECISION, 28% of men assigned to the MRI pathway did not undergo biopsy. Clinically significant prostate cancer was detected in 38% with the MRI strategy compared with 26% using standard biopsy, while clinically insignificant prostate cancer was detected in 9% versus 22%, respectively: PRIMARY2 had…...

1+ week, 6+ hour ago   (1256+ words) Katherine Amin reviews updates in pelvic organ prolapse repair. She highlights a 2026 AUGS and SGO consensus statement noting nearly 50% of women with gynecologic cancers have urinary incontinence, yet only 2% to 6% undergo concomitant pelvic floor repair, and confirming mesh is safe…...

1+ week, 6+ hour ago   (1057+ words) Dean Elterman presents the SUMMIT study. The Phase 4 real-world, prospective single-arm study evaluated the Optilume BPH Catheter System across five Canadian sites. Dr. Elterman reports a greater than 10-point improvement in IPSS and a more than 12-point improvement in Qmax…...